



DEPOSITARY RECEIPTS

NEW DR ANNOUNCEMENT

May 30, 2014

Benitec Biopharma Limited

Benitec Biopharma is an RNAi-based therapeutics company using its proprietary DNA-directed RNA interference technology to develop therapies for the treatment of life threatening diseases. The Company is engaged in the management and commercialization of therapeutic programs, funding, and building intellectual property estate. The Company's clinical pipeline is focused on opportunities in hepatitis B, lung cancer and cancer-associated neuropathic pain, as well as the orphan genetic disease, oculopharyngeal muscular dystrophy. The Company out-licenses its proprietary technology to biopharma companies for use in non-core therapeutic areas (hepatitis C, HIV/AIDS) and to global reagent suppliers for use in research.

DR Name:	Benitec Biopharma
Effective Date:	May 30, 2014
Country of Incorporation:	Australia
Exchange:	OTC
Type of ADR Program:	Sponsored - Level I
Ticker Symbol:	BTEBY
CUSIP Number:	082053208
Ratio:	1:5
Underlying Share Description:	Common
Industry Classification:	Pharma. & Biotech.
Local Custodian(s):	National Australia Bank Ltd

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Melissa Sobolewski/Ravi Davis
Adrdesk@bnymellon.com
Tel:212 815 2267

Hong Kong

Herston Powers
Vice President
herston.powers@bnymellon.com
Tel:852 2840 9868

London

Damon Rowan
Vice President
damon.rowan@bnymellon.com
Tel:442071637511

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contain herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.